Drug Origin Transparency Act of 2026

[AI summary unavailable — showing source text] [Congressional Bills 119th Congress] [From the U.S. Government Publishing Office] [H.R. 8339 Introduced in House (IH)] <DOC> 119th CONGRESS 2d Session H. R. 8339 To amend the Federal Food, Drug, and Cosmetic Act to enhance drug manufacturing amount information reporting, and for other purposes. _______________________________________________________________________ IN THE HOUSE OF REPRESENTATIVES April 16, 2026 Ms. Matsui (for herself, Mr. Crenshaw, Ms. Schrier, and Mrs. Hinson) introduced the following bill; which was referred to the Committee on Energy and Commerce _______________________________________________________________________ A BILL To amend the Federal Food, Drug, and Cosmetic Act to enhance drug manufacturing amount information reporting, and for other purposes. Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, SECTION 1. SHORT TITLE. This Act may be cited as the ``Drug Origin Transparency Act of 2026''. SEC. 2. ENHANCED DRUG MANUFACTURING AMOUNT INFORMATION REPORTING. (a) In General.--Section 510(j)(3) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360(j)(3)) is amended-- (1) in subparagraph …